Enlivex Therapeutics Ltd.
ENLV
NASDAQ·Healthcare·Biotechnology·Mkt cap $18.5M
$1.10
▼ -5.17%
P/E
—
Mkt Cap
$18.5M
52-Wk Range
$1.02–$27.15
52-Week Range
$1.02 - $27.15
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 93.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary macrophage reprogramming technology platform
- Differentiated cell-based therapy mechanism of action
- Advanced clinical stage development with Phase II data
- Intellectual property portfolio protecting core innovations
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Phase II clinical trial advancement and positive efficacy data for Allocetra
Value
Valuation data unavailable
Momentum
Falling
-89.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ENLV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 4, 2026
Reported EPS of -$0.31 vs -$0.31 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 3, 2026
vs Industry
How ENLV stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related